Identity:
Title: Prof.
Family Name(s): Van Linthout
First Name(s): Sophie, An, Stephanie, Dymphna
Age: 48

Application for the following position in the HFA Board or Nominating Committee:
Coordinator of the Basic Science Section

Photo:

Place of work *If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.*	
Institute/organisation:	Berlin Institute of Health (BIH) at Charité
Department:	BIH Center for Regenerative Therapies (BCRT)
Address:	Föhrerstrasse 15
Post code / Zip:	13353 Berlin
Country:	Germany

General Curriculum Vitae (500 words max)
Please also include your H index and top 5 to 10 publications in the last 5 years

University training and degree

2013	Private Instructor in experimental cardiology, Charité, University of medicine, Berlin, Germany
2002	Doctoral Thesis (PhD in medical science), Catholic University of Leuven, Belgium
1998	Bio-engineer in Cell- and Gene Biotechnology, Catholic University of Leuven, Belgium

Career

07/2023-	Head of the Inflammation Field, BCRT, Charité, Berlin, Germany
06/2021-	W2 professorship, BCRT
2017-	Research Group Leader: Translational immunocardiology, BCRT
2015-2017	Head of the experimental immunocardiology lab, AG Tschöpe, BCRT
2015-2023	Deputy Head of the Cardiovascular Systems Platform, BCRT
07/2010-03/2011	Parental leave
2010-2015	Subgroup leader, AG Tschöpe, Charité, BCRT
07/2007-01/2008	Parental leave
2004-2009	Post-Doc by Prof. Tschöpe, Charité, Department of Cardiology, Berlin, Germany
2003-2004	Post-Doc, Marie Curie Fellow of the European Commission by Prof. Madeddu, National Institute for Biostructures and Biosystems, Osilo, Italy
2002-2003	Post-Doc by Prof. De Geest, Center for Molecular & Vascular Biology, Leuven, Belgium
1998-2002	Doctoral Thesis work, PhD, Center for Molecular and Vascular Biology, Leuven, Belgium

Other

Fellowships:

2011	Lydia Rabinowitsch Stipendium, Charité, Berlin
2007	Research Stipendium, Charité, Berlin
2003-2004	Marie Curie Fellowship of the European Commission
1998-2002	Fellowship of the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)

Selected honors/elected memberships and committees:

06/2023-	Principal investigator at German Center for Cardiovascular Research (DZHK), Berlin
04/2023-	Co-Chair of the German Society of Cardiology (DGK) WG Myocardial Function and Energy
11/2022-	Guest editor of Circulation Heart Failure
09/2022-	Chair of the HFA Committee on Basic and Translational Research
01/2022-	Chair of the Gender Equality Acceleration Board of CRC1470
12/2021-	Fellow of the ESC (FESC)
2021-2023	Co-speaker of the BCRT
2020-	Board Member of the Heart Failure Association (HFA); Fellow of the HFA (FHFA)
2020-	BCRT steering committee member
2020-	*Ex-officio* nucleus member of the ESC Working Group on Cellular Biology of the Heart (CBH)
2020-2023	Chair of the DZHK grant evaluation board, Berlin
2020-2023	Organization Committee Member of the Science Forum, BCRT
2019-	Doctoral Committee Member, Charité

Selected publications

h-index: 48

1. Poetsch MS[*], Palus S[*], **Van Linthout S**, et al. The small molecule ACM-001 improves cardiac function in a rat model of severe cancer cachexia. *Eur J Heart Fail* 2023.
2. Pesce M et al. **Van Linthout S.** Cardiac fibroblasts and mechanosensation in heart development, health and disease. *Nat Rev Cardiol* 2022.
3. Matz I et al. **Van Linthout S.** Left ventricle- and skeletal muscle-derived fibroblasts exhibit a differential inflammatory and metabolic responsiveness to interleukin-6. *Front Immunol* 2022.
4. Pappritz K et al. Tschöpe C[*], **Van Linthout S[*].** Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis. *ESC Heart Fail* 2022.
5. Tschöpe C et al. **Van Linthout S.** Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. *Nat Rev Cardiol* 2021.
6. Müller I et al. **Van Linthout S[*]**, Tschöpe C[*]. Serum alarmin S100A8/A9 levels and its potential role as biomarker in myocarditis. *ESC Heart Fail* 2020.
7. Spillmann F, **Van Linthout S**, et al. Mode-of-action of the PROPELLA concept in fulminant myocarditis. *Eur Heart J* 2019.

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society
150 words maximum

I have the honor of being a member of the ESC Working Group on Cellular Biology of the Heart since 2016, a member of the HFA Board since 2020 and Chair of the HFA Committee on Basic and Translational Research since 2022. During these mandates, I have had the opportunity to contribute to or lead more than 15 scientific documents/opinion papers and position papers. At the HFA, I have also undertaken auxiliary roles such as supporting the organization of the Winter Heart Failure Meeting, as well as evaluating grants to bolster young clinical and basic/translational scientists in their endeavours. These tasks are driven by my devotion to the HFA and ESC and my motivation: "Improving quality of life and life expectancy through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research", according to the HFA mission statement.

Why are you motivated to join the HFA Board or Nominating Committee?
150 words maximum

As a basic and translational scientist, I am keen to advance the translation of basic research into the clinic. I believe that progress in the fight against heart failure depends on close interaction between basic scientists and clinicians, enabling a continuous and two-way flow of knowledge and clinical practice and practicality. My ambitioned role as Coordinator of the Basic Research Section will allow to play a decision-making role in promoting interaction between clinical and basic scientists within the HFA community in close collaboration with the young HFA, increasing the visibility of basic/translational research to address unmet medical needs, assisting in the innovative training of the next generation of heart failure scientists, and raising awareness of the need of sex-specific translational research. I am endeavouring to launch a journal that will serve as a platform for the dissemination of basic scientific discoveries facilitating translation in the clinical realm.

How will you combine your HFA position with your daily clinical/research workload?
80 words maximum

As a devoted HFA member, I am keen at allocating time and efforts for my HFA responsibilities. My two last HFA mandates express my ability to combine my daily research activities with my HFA roles, and even more, with chairing or being a member of many committees in the Berlin research landscape. Building on these experiences and mandates, I am certain that I can combine the HFA position as Coordinator of the Basic Research Section with my research workload.